{"filings":[{"id":108967,"accession_number":"0001493152-26-006428","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.","Net loss of $2.0M ($0.05/shr) vs $2.5M ($0.09/shr) in same quarter prior year.","Operating expenses flat at $2.6M; cash $9.0M plus $3.0M loan facility available.","Lead candidate selonabant: IV formulation Phase 1 SAD study started Sep 2025; prioritizing pediatric pathway.","Company cites cost savings from ending public reporting obligations as rationale for delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108966,"accession_number":"0001493152-26-005463","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Anebulo Pharmaceuticals voluntarily delisting from Nasdaq, terminating SEC registration effective Feb 27, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved voluntary delisting from Nasdaq and deregistration with SEC on Feb 5, 2026; Nasdaq notified Feb 6.","Form 25 to be filed on or about Feb 17; delisting expected effective Feb 27, 2026.","Form 15 to be filed on or about Feb 27 certifying fewer than 300 record holders, suspending SEC reporting.","Company is in compliance with Nasdaq rules; delisting decision based on cost of public company burdens outweighing benefits.","Following delisting, trading will occur only in privately negotiated sales or on the OTC market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108965,"accession_number":"0001493152-26-004154","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo completes oversubscribed tender offer, buys 300K shares at $3.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final count: 4,907,881 shares tendered, oversubscribed.","Accepted 300,000 shares (incl. 134,306 odd lots) at $3.50/share for ~$1.05M.","Proration factor 3.47392%; accepted shares = 0.73% of shares outstanding.","CEO: pleased to provide smaller stockholders opportunity to sell at premium to market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108964,"accession_number":"0001493152-26-003718","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo tender offer oversubscribed; 4.9M shares tendered, 300k accepted at $3.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,897,188 shares properly tendered (excluding 10,868 by guaranteed delivery).","Company expects to accept 300,000 shares at $3.50 each for total cost of ~$1.05M.","Proration factor approximately 3.51542%; odd lots accepted in full.","Shares accepted represent about 0.73% of outstanding as of Jan 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125416,"accession_number":"0001493152-25-028676","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo abandons reverse split, launches self-tender for up to 300k shares at $3.50/sh to go private","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abandons reverse stock split (1-for-2,500 to 1-for-7,500) due to cost increase from holders splitting shares to get multiple fractional payments.","Launches self-tender offer to purchase up to 300,000 shares at $3.50 per share, aggregate up to $1.05 million.","Tender offer designed to reduce stockholder count below 300, necessary for 'go private' transaction.","Board may revisit reverse split or alternative transaction in future if economically beneficial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125415,"accession_number":"0001493152-25-022310","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.","Cash $10.4M at Sept 30, 2025; plus $3M available under loan agreement.","First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric cannabis toxicity; FDA-cleared design.","Received $994,300 second-year tranche of NIDA/NIH grant to support the SAD study.","Board continues strategic review including proposed reverse stock split and going-private transaction; SEC comments delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142152,"accession_number":"0001493152-25-016001","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).","First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric acute cannabis toxicity on September 25, 2025.","Received year-2 NIDA/NIH grant of $994,300 to support the SAD study of IV selonabant.","Board approved reverse stock split to reduce record holders below 300 as part of proposed going-private transaction; special meeting pending.","Cash and cash equivalents $11.6M at June 30, 2025; additional $3M available under loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142151,"accession_number":"0001493152-25-013133","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo updates on going private: Board to consider sale, merger, or other alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received inbound interest from potential financial and strategic partners after announcing going private on July 23, 2025.","Board will review all strategic alternatives including going private, reverse stock split, asset sale, or merger.","Company plans to hold special stockholder meeting to approve proposed reverse stock split while review continues.","No assurance that process will result in a transaction; no deadline or definitive timetable set.","Even if stockholders approve reverse stock split, Board could abandon it for any reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142150,"accession_number":"0001493152-25-011342","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo plans going-private via reverse split; $3.50/share for fractional shares, 91% premium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio range 1-for-2,500 to 1-for-7,500; stockholder vote at special meeting Aug 22, 2025.","Cash payment of $3.50 per pre-split share for fractional shares, representing a 91% premium to July 22 close.","Holders below 2,500-7,500 pre-split shares will be cashed out; holders above retain one post-split share per minimum.","Transaction aims to reduce record holders below 300 to terminate SEC registration; board may abandon at any time.","Company cites high cost of being public as burdensome; will focus on advancing selonabant IV formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160141,"accession_number":"0001641172-25-009952","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.","Net loss $1.7M ($0.04/share) vs $1.7M ($0.06/share) in prior year.","Cash $13.3M plus $3M loan facility; sufficient for planned operations.","Prioritizing IV selonabant for pediatric CNS depression; Phase 1 SAD study to start Q3 2025.","FDA confirmed unmet need for pediatric cannabis toxicity treatment; collaboration suggested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160140,"accession_number":"0001641172-25-004799","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Anebulo regains Nasdaq compliance on private placement share restrictions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5635(b) on April 11, 2025.","Removal of voting and transfer restrictions on shares issued in December 2024 private placement was approved by stockholders.","Matter is now closed; no further delisting risk from this issue.","Company disclosed the resolution in an 8-K filed April 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160139,"accession_number":"0001641172-25-003913","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Anebulo shareholders approve authorized share increase to 75M and board declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved raising authorized common shares from 50M to 75M at the April 4, 2025 Annual Meeting.","Certificates of amendment filed with Delaware on April 11, 2025.","Stockholders also approved declassification of the Board; all directors will stand for annual election starting next meeting.","Board adopted conforming Bylaws amendment effective upon the declassification charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160138,"accession_number":"0001641172-25-002862","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anebulo shareholders approve authorized share increase to 75M, stock plan expansion, and removal of 10.1M-share lock-up","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 50M to 75M shares; stock incentive plan pool raised by 2.5M to 6.15M shares.","Voting and transfer restrictions on 10,101,010 shares held by 22NW Fund, LP removed per shareholder approval.","Class I directors Joseph F. Lawler, Richard Anthony Cunningham, Aron R. English re-elected.","Ratification of EisnerAmper LLP as independent auditor for fiscal 2025 approved.","All proposals passed with strong majorities; record date had 41,084,731 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178453,"accession_number":"0001493152-25-008080","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.","Company entered lock-up agreement with 22NW (Aron English) on Feb 24, 2025, restricting voting/sale of 10.1M shares until stockholder approval.","Nasdaq granted extension until April 10, 2025 to obtain stockholder approval; annual meeting scheduled April 4, 2025.","Joseph Lawler entities have agreed to vote in favor of removing lock-up restrictions, which would ratify the change of control.","Failure to obtain stockholder approval by April 10, 2025 may result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178452,"accession_number":"0001493152-25-006875","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q2 FY2025 net loss $2.5M ($0.09/sh); secures $15M private placement; FDA supports pediatric plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.","Cash and equivalents $15.0M as of Dec 31, 2024; additional $3M available under amended loan.","FDA acknowledged unmet need for pediatric cannabis toxicity treatment; Phase 1 SAD study of IV selonabant expected in H1 2025.","Closed $15M private placement with 22NW Fund, issuing 15.2M shares.","Amended loan with 22NW and JFL, reducing max to $3M and removing securitization."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178451,"accession_number":"0001493152-25-006036","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Anebulo sets 2025 annual meeting for April 4; stockholder proposals due Feb 22","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for April 4, 2025; location to be in proxy materials.","Stockholder proposals for inclusion in proxy must be received by February 22, 2025.","Director nominations and other proposals not in proxy also due by February 22, 2025.","Universal proxy rule compliance deadline is February 22, 2025 (10 days after 8-K filing).","Meeting date more than 30 days after prior year's anniversary, resetting prior deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195121,"accession_number":"0001493152-24-051853","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.02","5.01","8.01","9.01"],"status":"ready","headline":"Anebulo raises $15M via private placement, FDA supports development of IV selonabant for pediatric cannabis toxicity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.","FDA acknowledged unmet need for pediatric cannabis toxicity and proposed close collaboration to efficiently advance IV selonabant program.","Plans to begin Phase 1 SAD study of IV selonabant in healthy adults in 1H 2025.","Will modify Loan & Security Agreement with 22NW and JFL Capital: reduce max loan to ~$3M, remove securitization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195120,"accession_number":"0001493152-24-045133","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.","Operating expenses of $2.4M, down from $2.5M year-over-year.","Cash $1.4M at Sept 30, 2024; access to $10M loan facility.","Awarded $1.9M NIDA grant to support IV selonabant development.","Plans to enroll first healthy volunteer in IV study in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195119,"accession_number":"0001493152-24-041362","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anebulo updates corporate presentation; no specific changes disclosed in filing extract","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated Corporate Presentation as Exhibit 99.1 under Item 7.01.","Presentation content is not included in the provided text; details of updates are unknown.","No forward-looking statements or material financial data were available for review.","Investors should request the full presentation from the company for substantive changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211398,"accession_number":"0001493152-24-038112","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma reports Q4 FY2024 net loss $0.05/share; net loss down 48% YoY; awarded $1.9M NIDA grant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.","Full-year FY2024 net loss $8.2M ($0.32/sh) vs $11.7M ($0.47/sh) in FY2023.","Cash and equivalents $3.1M at June 30, 2024; additional $10M available under loan agreement.","Awarded up to $1.9M NIDA grant for IND-enabling activities for IV selonabant for pediatric cannabis poisoning.","Expects to enroll first healthy volunteer in H1 2025 for IV formulation clinical study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211397,"accession_number":"0001493152-24-028629","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo awarded up to $1.9M NIDA grant for IV selonabant development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.","Initial tranche $0.9M awarded; second tranche ~$1M subject to milestone achievements.","Program targets pediatric cannabis-induced CNS depression, a serious unmet medical need.","CEO notes grant validates progress and supports IV formulation clinical testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230024,"accession_number":"0001493152-24-024096","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo adopts new non-employee director equity compensation policy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial grant of option to purchase 50,000 shares, vesting monthly over 3 years.","Annual grant of option to purchase 25,000 shares, vesting 1 year or next annual meeting.","All options expire 10 years from grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230023,"accession_number":"0001493152-24-019877","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).","Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.","Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.","DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.","Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}